Antiretroviral therapy and declining AIDS mortality in New York City

Medical Care

Volumn 41, Issue 4, 2003, Pages 512-521

  Messeri, Peter ^a   Gunjeong, Lee ^a   Abramson, David M ^a   Aidala, Angela ^a   Chiasson, Mary Ann ^b   Jessop, Dorothy Jones ^b  

^a Columbia University ^*  (United States)

^b Health Research Association   (United States)

Author keywords

Antiretroviral therapy; HIV AIDS; Mortality

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; ETHNOLOGY; FEMALE; HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOLOGY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; SEX RATIO; SOCIOECONOMICS; SURVIVAL; SURVIVAL RATE; UNITED STATES; UTILIZATION REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HUMANS; MALE; NEW YORK CITY; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; URBAN HEALTH;

EID: 85047695932     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MLR.0000053230.81725.EF     Document Type: Article

References (25)

1. HIV/AIDS Surveillance Report. Atlanta: Center for Disease Control and Prevention. 2000;12:38.
2. Chiasson MA, Berenson L, Li W, et al. Declining HIV/AIDS mortality in New York City. J Acquired Immune Deficiency Syndromes 1999;21:59-64.
3. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179:717-720.
4. Liu KL, Loberti PG Jr, Minuto L. AIDS morbidity and mortality in Rhode Island. Medicine and Health, Rhode Island 1998;1:217-218.
5. Hogg RS, O'Shaughnessy M, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
6. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-1730
7. Brettle RP, Wilson A, Povey S, et al. Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients. Int J STD AIDS 1998;9:80-87.
8. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-1669.
9. Delta Coordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-291.
10. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
11. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1997;337:1091-1098.
12. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combinaion therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-1090.
13. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group Lancet 1998;351:543-549.
14. Chiesi A, Mocroft A, Dally LG, et al. Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS 1999;13:2281-2288.
15. Messeri P, Weinberg G. Sample Design for Staffing Needs and Client Survey Studies. CHAIN Technical Report #1. Columbia University, Mailman School of Public Health. 1994.
16. Messeri P, Aidala A, Abramson D, et al. Recruiting rare & hard to reach populations: A sampling strategy for surveying NYC residents living with HIV/AIDS using agency recruiters. In 50th Annual Conference of the American Statistical Association, Section on Survey Research Methods, Vol II. 1995.
17. Messeri P, Aidala A, Jessop DJ, et al. Applying rigorous sampling strategies for studying hard-to-reach populations: Are the results worth the effort? In: Abstracts of the 52nd Annual Conference of the American Association for Public Opinion Research. 1997.
18. Messeri P, Abramson D, Aidala A, et al. The Impact of Ancillary HIV Services on Engagement in Med Care in New York City. AIDS Care 2002;14(Suppl 1):S15-S29.
19. Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. The Health Institute, New England Medical Center. 1994.
20. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: Wiley; 1980.
21. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons; 1987:75-99
22. Messeri, P. Trends in Current Use of HIV Antiretroviral Therapy. CHAIN Update Report #19. Columbia University, Mailman School of Public Health. 1999.
23. New York City Department of Health, Office of AIDS Surveillance. Estimates of persons living with AIDS in New York City. March 2000.
24. Abramson D, Sanger N, Messeri P, et al. Assessing the Impact of the Ryan White CARE Act on Health Outcomes in New York City. Final Report to the Health Resources & Services Administration. Columbia University, Mailman School of Public Health. November 2001.
25. Genealogy and Family History. Available at: http://www.ancestry. com. Accessed January 13, 2003.